Response of refractory Ewing sarcoma to pazopanib
Author:
Affiliation:
1. Departments of Oncology and Medicine, McGill University, Montreal, Quebec, Canada
Publisher
Informa UK Limited
Subject
Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.3109/0284186X.2014.971938
Reference8 articles.
1. Therapy resistance mechanisms in Ewing’s sarcoma family tumors
2. Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors
3. Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma
4. Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clinicopathological and molecular genetic analysis of 13 cases of primary retroperitoneal Ewing sarcoma;Annals of Diagnostic Pathology;2024-10
2. Current status and future directions of systemic therapy in high-grade bone sarcomas;N.N. Priorov Journal of Traumatology and Orthopedics;2024-07-04
3. Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma;Oncoscience;2023-09-20
4. Targeted Treatment of Soft-Tissue Sarcoma;Journal of Personalized Medicine;2023-04-26
5. Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma;Frontiers in Oncology;2023-03-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3